Stocks
Health Care
anl
Adlai Nortye
NASDAQ: ANL
+4.03 (+61.72%)
10.56
USD
At close at Jan 30, 21:46 UTC
Overview
Loading chart...
Key Stats
Market Cap
391.86M
Dividend Yield
0.00%
P/E Ratio
0.00
EPS
-3.98
Revenue
-
Avg. Volume
2.95M
Recently from Cashu
No Cashu articles
Adlai Nortye currently has no Cashu-related articles
About
What does ANL do?
Adlai Nortye is a clinical-stage biopharmaceutical company developing cancer therapies, including three clinical candidates: AN2025, AN0025, and AN4005, along with three preclinical candidates. AN2025 is in Phase III trials for treating recurrent head and neck squamous cell carcinomas.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.